Core Viewpoint - Wall Street analysts anticipate Royalty Pharma (RPRX) will report quarterly earnings of $0.99 per share, reflecting a year-over-year increase of 1%, with revenues expected to reach $793.58 million, up 10.7% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1] - The consensus estimate for 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' is projected at $234.18 million, representing a year-over-year change of +7.2% [4] - Analysts predict 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' will reach $58.87 million, indicating a decline of -14.8% year over year [4] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is $45.35 million, reflecting a decrease of -9.4% year over year [5] - The average prediction for 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is $49.97 million, showing an increase of +21.8% year over year [5] - Analysts expect 'Portfolio Receipts- Royalty Receipts- Products- Promacta' to reach $34.38 million, indicating a decline of -19.2% from the prior year [6] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is $38.91 million, reflecting an increase of +7.6% year over year [6] - The consensus for 'Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq' is $21.62 million, indicating a year-over-year increase of +21.3% [7] - Analysts project 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' to be $51.98 million, reflecting a change of +15.6% from the prior year [7] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is $11.32 million, indicating a change of +10.2% year over year [8] - The total estimate for 'Portfolio Receipts- Royalty Receipts- Products- Total' is projected at $777.88 million, suggesting a year-over-year increase of +10.4% [8] - Analysts forecast 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' to reach $84.96 million, reflecting a year-over-year change of +20.4% [9] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Nurtec ODT/Zavzpret' is projected at $9.01 million, indicating a significant increase of +43.9% year over year [9] Stock Performance - Shares of Royalty Pharma have increased by +5.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.4% change [9]

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collabor ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view th ...

Group 1 - Royalty Pharma appointed Vlad Coric, M.D. to its Board of Directors, effective immediately [1][2] - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company with a focus on neuroscience, immunology, and oncology [1][2] - Coric's leadership at Biohaven included the FDA approval and launch of Nurtec ODT for migraine treatment and the filing of an NDA for zavegepant [2][3] - Under Coric's leadership, Biohaven grew significantly and was sold to Pfizer for approximately $13 billion in May 2022 [2] Group 2 - Coric has over 20 years of experience in drug discovery and clinical development, with expertise in various therapeutic areas [3] - His educational background includes a medical degree from Wake Forest University and a Bachelor of Science degree from the University of Connecticut [3] - Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry [4] - The company collaborates with a range of entities, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties on over 35 commercial products [4]

Core Insights - Royalty Pharma plc has appointed Vlad Coric, M.D. to its Board of Directors, effective immediately, enhancing its leadership team with his extensive biopharmaceutical experience [1][2]. Group 1: Appointment and Leadership - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company focused on neuroscience, immunology, and oncology [1][2]. - Pablo Legorreta, CEO of Royalty Pharma, expressed excitement about Coric's appointment, highlighting his entrepreneurial approach and leadership skills as valuable assets [2]. - Coric has notable experience in royalty funding, having completed multiple transactions with Royalty Pharma during his time at Biohaven [2]. Group 2: Achievements and Experience - Under Coric's leadership, Biohaven achieved FDA approval and launched Nurtec ODT for migraine treatment, and filed an NDA for zavegepant, the first intranasal CGRP antagonist for ultra-rapid migraine relief [2]. - Coric oversaw Biohaven's growth from its founding to its sale to Pfizer in May 2022 for approximately $13 billion [2]. - He has over 20 years of experience in drug discovery and clinical development, with expertise across various therapeutic areas including neurology, psychiatry, and oncology [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [4]. - The company collaborates with a range of innovators, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties based on top-line sales of leading therapies [4]. - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 15 development-stage candidates, indicating a strong position in the biopharmaceutical market [4].

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Addi ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...

Following our recent update on Royalty Pharma plc (NASDAQ: RPRX ) - Key Strategic Updates To Be Priced In , we are back to comment on the company's quarterly results. Since our strong buy recommendation released in earlyBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ 110 East 59 Street th New York, New York 10022 (Address of principal executive offices and Zip Code) (212) 883-0200 (Registrant's telephone ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). "We are excited to collaborate with Biogen on litifilimab," said Pablo Legorreta, Royalty Pharma's fou ...